The problem is the cost, in Europe and the USA the treatment is over $40,000 USD per year, which isn't realistic for regular people.
All in all, HIV just isn't a problem anymore. It's on the same sort of threat scale as any other STD. Even if you're infected, you just continue taking PrEP (technically PEP) for the rest of your life and that's about it. Normal life expectancy and not much other health complications for most people with consistent treatment.
The $40k+ price is the cost of the 2x pa injectable form. This is a relatively newer treatment and not widespread.
There have been many failed attempts at developing suppressive, curative and preventative medicine against HIV over the decades, and not all of that was funded by charities or government grants that don't expect repayment - especially not the later stage trials.
If only we had an institution with the aim of pursuing the long-term interests of the collective.
Generics aren't possible in markets where the patent holder enforces their rights. The article is about how Gilead will allow certain poverty ridden countries to access the drug without the need to pay a licensing cost (i.e. they can receive a "generic").